Mask Ventilation With Different Face Masks During Neonatal Resuscitation
Launched by UNIVERSITY OF ALBERTA · Sep 11, 2012
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
We will use a Laerdal round mask (Laerdal, Stavanger, Norway) compared to a Fisher \& Paykel (FP) (Fisher \& Paykel Healthcare, Auckland, New Zealand) 'round' neonatal resuscitation mask. The two point top hold for Laerdal 'round' mask and the rim hold for the Fisher \& Paykel mask.
A Respiratory Function Monitor will be placed between the face mask and the ventilation device. It uses a small (dead space 1 mL) flow sensor to measure gas flow in and out of a face mask. This signal is automatically integrated to provide inspired and expired tidal volume. The difference equals the leak from t...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Preterm infants \<32 weeks gestation born at The Royal Alexandra Hospital who require resuscitation in the delivery room will be recorded.
- Exclusion Criteria:
- • Infants will be excluded from final analysis if they have a congenital abnormality or condition that might have an adverse effect on breathing or ventilation, including: Congenital Diaphragmatic Hernia. Infants will also be excluded if their parents refuse to give consent to this study.
- • Participants will be included in the first minutes after birth if they require mask ventilation for poor respiratory effort. Data will be collected from the Hospital chart until discharge at around 40 weeks gestation.
About University Of Alberta
The University of Alberta, a leading research institution in Canada, is dedicated to advancing healthcare through innovative clinical trials. With a strong commitment to scientific excellence and community health, the university facilitates cutting-edge research across various medical disciplines. Its interdisciplinary approach fosters collaboration among researchers, clinicians, and students, ensuring that clinical trials are designed and conducted with the utmost rigor and ethical standards. By leveraging its extensive resources and expertise, the University of Alberta aims to translate research findings into meaningful advancements in patient care and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Edmonton, Alberta, Canada
Patients applied
Trial Officials
Georg Schmolzer, MD,PhD
Principal Investigator
University of Alberta
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials